![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CytoDyn and Chiral Pharma will work together to register leronlimab (PRO 140) for potential approval from the local Food and Drug Administration to treat patients with COVID-19 in the Philippines.
Lead Product(s): Leronlimab
Therapeutic Area: Infections and Infectious Diseases Product Name: PRO 140
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: CytoDyn
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 12, 2020